FUENZALIDA E, PALACIOS R, BORGONO J M
Bull World Health Organ. 1964;30(3):431-6.
Antirabies vaccines produced from infected brains of adult mammals have always had the potentiality of causing post-vaccinal paralysis or allergic encephalitis in man. Attempts in recent years either to remove the paralytic factor from brain-tissue vaccines or to use as the virus source infected tissue other than nervous tissue (e.g., chick embryos) have usually resulted in a substantial reduction of the specific antirabies potency.The authors' laboratory had previously developed a vaccine made from infected suckling-mouse brains in which the virus was inactivated by ultraviolet irradiation. This vaccine was found highly potent in animal tests and low in organ-specific antigens. Others have found the brains of newborn mammals to be free of the allergic encephalitic factor. The studies reported in this paper show that the antirabies antibody responses to a 14-dose course of this suckling-mouse-brain vaccine in children are at a high level even when the vaccine is used at a 1% tissue concentration. There was no evidence of deleterious reactions to this treatment in 31 children.It is concluded that these results justify a long-term trial of this vaccine for antirabies prophylaxis in man.
由成年哺乳动物感染的脑组织制成的狂犬病疫苗一直存在使人发生接种后麻痹或过敏性脑炎的可能性。近年来,人们试图从脑组织疫苗中去除麻痹因子,或使用神经组织以外的感染组织(如鸡胚)作为病毒来源,但这通常会导致特异性抗狂犬病效力大幅降低。作者所在实验室此前研制了一种由感染的乳鼠脑制成的疫苗,其中病毒通过紫外线照射灭活。这种疫苗在动物试验中被发现效力很高,且器官特异性抗原含量很低。其他人发现新生哺乳动物的大脑不含过敏性脑炎因子。本文报道的研究表明,即使以1%的组织浓度使用这种乳鼠脑疫苗,儿童在接种14剂疗程后产生的抗狂犬病抗体反应仍处于高水平。31名儿童中没有证据表明这种治疗有有害反应。结论是,这些结果证明对这种疫苗进行人体抗狂犬病预防的长期试验是合理的。